EA006628B1 - Способы амплификации и размножения хордопоксвируса - Google Patents
Способы амплификации и размножения хордопоксвируса Download PDFInfo
- Publication number
- EA006628B1 EA006628B1 EA200400195A EA200400195A EA006628B1 EA 006628 B1 EA006628 B1 EA 006628B1 EA 200400195 A EA200400195 A EA 200400195A EA 200400195 A EA200400195 A EA 200400195A EA 006628 B1 EA006628 B1 EA 006628B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- temperature
- cells
- vaccine
- chordopoxvirus
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims description 71
- 229960005486 vaccine Drugs 0.000 claims description 33
- 230000002238 attenuated effect Effects 0.000 claims description 12
- 230000000644 propagated effect Effects 0.000 claims description 10
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 241000700663 Avipoxvirus Species 0.000 claims description 5
- 241000700629 Orthopoxvirus Species 0.000 claims description 5
- 210000002257 embryonic structure Anatomy 0.000 claims description 5
- 238000001415 gene therapy Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 7
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 10
- 241000700647 Variola virus Species 0.000 description 9
- 238000011534 incubation Methods 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 241000700570 unidentified entomopoxvirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000005585 Poxviridae Infections Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 241001290610 Abildgaardia Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 206010046861 Vaccination complication Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101122 | 2001-07-18 | ||
| PCT/EP2002/007280 WO2003008533A2 (en) | 2001-07-18 | 2002-07-02 | Method for virus propagation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200400195A1 EA200400195A1 (ru) | 2004-06-24 |
| EA006628B1 true EA006628B1 (ru) | 2006-02-24 |
Family
ID=8160630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200400195A EA006628B1 (ru) | 2001-07-18 | 2002-07-02 | Способы амплификации и размножения хордопоксвируса |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6924137B2 (enExample) |
| EP (1) | EP1412486B1 (enExample) |
| JP (2) | JP4700907B2 (enExample) |
| KR (1) | KR100908377B1 (enExample) |
| CN (1) | CN100513560C (enExample) |
| AU (1) | AU2002314201B2 (enExample) |
| BR (2) | BRPI0211276B1 (enExample) |
| CA (1) | CA2450206C (enExample) |
| DE (1) | DE60223812T2 (enExample) |
| DK (1) | DK1412486T3 (enExample) |
| EA (1) | EA006628B1 (enExample) |
| HU (1) | HUP0400393A3 (enExample) |
| IL (2) | IL158927A0 (enExample) |
| MX (1) | MXPA04000326A (enExample) |
| NO (1) | NO339056B1 (enExample) |
| NZ (1) | NZ529914A (enExample) |
| PL (1) | PL205926B1 (enExample) |
| UA (1) | UA82466C2 (enExample) |
| WO (1) | WO2003008533A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1335987T4 (en) * | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
| WO2004022729A1 (en) * | 2002-09-05 | 2004-03-18 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| TWI638829B (zh) | 2012-07-10 | 2018-10-21 | 法商傳斯堅公司 | 分枝桿菌抗原疫苗 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| US10765731B2 (en) | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| US10913063B2 (en) * | 2016-07-12 | 2021-02-09 | EMULATE, Inc. | Removing bubbles in a microfluidic device |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| SG11201912429RA (en) | 2017-06-21 | 2020-01-30 | Transgene Sa | Personalized vaccine |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| AU2024241503A1 (en) | 2023-03-17 | 2025-08-14 | Albert-Ludwigs-Universität Freiburg | Hbv antigen formulation for treating hepatitis b |
| WO2025172435A1 (en) | 2024-02-13 | 2025-08-21 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Hbv antigen formulation for treating hepatitis b |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2384845A1 (fr) * | 1976-08-05 | 1978-10-20 | Anvar | Vaccin contre la myxomatose et nouvelle souche virale utilisee |
| JPS60202827A (ja) * | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| WO1997012032A1 (en) * | 1995-09-27 | 1997-04-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| EP0912724B1 (en) * | 1996-07-15 | 2009-12-09 | The Government of The United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| DK1335987T4 (en) * | 2000-11-23 | 2016-09-19 | Bavarian Nordic As | Modified variant of vaccinia virus Ankara |
-
2002
- 2002-02-07 UA UA2004010355A patent/UA82466C2/uk unknown
- 2002-07-02 HU HU0400393A patent/HUP0400393A3/hu unknown
- 2002-07-02 JP JP2003514077A patent/JP4700907B2/ja not_active Expired - Fee Related
- 2002-07-02 WO PCT/EP2002/007280 patent/WO2003008533A2/en not_active Ceased
- 2002-07-02 CA CA2450206A patent/CA2450206C/en not_active Expired - Fee Related
- 2002-07-02 AU AU2002314201A patent/AU2002314201B2/en not_active Ceased
- 2002-07-02 EA EA200400195A patent/EA006628B1/ru not_active IP Right Cessation
- 2002-07-02 US US10/483,707 patent/US6924137B2/en not_active Expired - Lifetime
- 2002-07-02 NZ NZ529914A patent/NZ529914A/en not_active IP Right Cessation
- 2002-07-02 CN CNB02814421XA patent/CN100513560C/zh not_active Expired - Fee Related
- 2002-07-02 DE DE60223812T patent/DE60223812T2/de not_active Expired - Lifetime
- 2002-07-02 MX MXPA04000326A patent/MXPA04000326A/es active IP Right Grant
- 2002-07-02 DK DK02740758T patent/DK1412486T3/da active
- 2002-07-02 BR BRPI0211276A patent/BRPI0211276B1/pt unknown
- 2002-07-02 KR KR1020047000786A patent/KR100908377B1/ko not_active Expired - Fee Related
- 2002-07-02 EP EP02740758A patent/EP1412486B1/en not_active Revoked
- 2002-07-02 IL IL15892702A patent/IL158927A0/xx unknown
- 2002-07-02 BR BR0211276-0A patent/BR0211276A/pt not_active IP Right Cessation
- 2002-07-02 PL PL366897A patent/PL205926B1/pl unknown
-
2003
- 2003-11-18 IL IL158927A patent/IL158927A/en not_active IP Right Cessation
-
2004
- 2004-01-13 NO NO20040158A patent/NO339056B1/no not_active IP Right Cessation
-
2010
- 2010-11-22 JP JP2010259770A patent/JP5154632B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA006628B1 (ru) | Способы амплификации и размножения хордопоксвируса | |
| JP4759201B2 (ja) | 変異ワクシニアウイルスアンカラ（ｍｖａ）の改変株 | |
| US8329466B2 (en) | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions | |
| JP2004535203A5 (enExample) | ||
| AU2002314201A1 (en) | Method for virus propagation | |
| HUT52555A (en) | Process for production of virus and vaccina against recombinant marek-desease | |
| UA123682C2 (uk) | Вірус качиного ентериту та його застосування | |
| US6241989B1 (en) | Recombinant multivalent viral vaccine | |
| TWI224139B (en) | Processes for preparation of Marek's disease virus using continuous avian cell lines | |
| EA013404B1 (ru) | Применение модифицированных поксвирусов для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов | |
| US6942864B2 (en) | Leporipox-based vector vaccines | |
| US5833980A (en) | Sustainable cell line for the production of the Marek's disease vaccines | |
| US7087234B1 (en) | Recombinant multivalent viral vaccine | |
| AU2002304856A1 (en) | Leporipox-based vector vaccines | |
| JP2006509526A (ja) | トリ胚性幹細胞上におけるａｌｖａｃの産生 | |
| JPH104956A (ja) | マレク病ワクチン製造のための維持可能な細胞株の改良 | |
| HK1066245B (en) | Method for virus propagation | |
| Shinagawa et al. | Origin of thymidine kinase in the cells infected with infectious canine hepatitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |